Abstract
Background/Purpose
Family history of coronary artery disease (CAD) is a well-established risk factor of future cardiovascular events. The authors sought to examine the relationship between family history of CAD and clinical profile and prognosis of patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
Materials/Methods
Baseline features and clinical outcomes at 30 days and at 3 years from 3601 patients with STEMI enrolled in the HORIZONS-AMI trial were compared in patients with and without family history of premature CAD, which was present in 1059 patients (29.4%).
Results
These patients were younger (median 56.7 vs. 62.1 years, P < 0.0001) and more often current smokers (52.4% vs. 43.5%, P < 0.0001), had more dyslipidemia (47.7% vs. 41.1%, P = 0.0003), less diabetes mellitus (14.1% vs. 17.5%, P = 0.01) and had shorter symptom onset to balloon times (median 213 vs. 225 min, P = 0.02). Patients with a family history of premature CAD had higher rates of final TIMI 3 flow (93.8% vs. 90.6%, P = 0.002), and myocardial blush grade 2 or 3 (83.2% vs. 78.0% P = 0.0008), and fewer procedural complications. Although the unadjusted 30-day and 3-year mortality rates were lower in patients with a family history of premature CAD (1.8% vs. 3.0%, P = 0.046 and 4.8% vs. 7.7%, P = 0.002, respectively), by multivariable analysis the presence of a family history of premature CAD was not an independent predictor of death at 3 years (HR [95%CI] = 1.00 [0.70, 1.44], P = 0.98).
Conclusions
A family history of premature CAD is not an independent predictor of higher mortality.
Highlights
- •
Patients with and without a family history of CAD were compared.
- •
Family history patients were younger, more often smokers, and had more dyslipidemia.
- •
History patients had better angiographic outcomes post-PCI.
- •
Family history of premature CAD was not an independent predictor of 3-year mortality.
1
Introduction
The Framingham Heart Study established a family history of coronary artery disease (CAD), defined as cardiovascular disease occurring in parents, siblings, or children, to be a risk factor for the occurrence of a first adverse cardiovascular event in patients without known CAD . This has been supported by other series . However, the baseline characteristics and prognosis of patients with vs. without family history of premature CAD with ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) are unknown . We therefore examined the Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS-AMI) trial database to assess the relationship between family history of premature CAD and adverse events in patients presenting STEMI undergoing primary PCI with contemporary antithrombotic regimens .

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

